Occurrence of Comorbidities before and after Soft Tissue Sarcoma Diagnosis by van Herk-Sukel, Myrthe P. P. et al.
Hindawi Publishing Corporation
Sarcoma
Volume 2012, Article ID 402109, 7 pages
doi:10.1155/2012/402109
Research Article
Occurrenceof Comorbiditiesbefore and after Soft Tissue
Sarcoma Diagnosis
Myrthe P. P. van Herk-Sukel,1 SumitraShantakumar,2 Lucy I. H. Overbeek,3
Hester van Boven,4 FernieJ. A. Penning-vanBeest,1 andRon M. C. Herings1,5
1PHARMO Institute for Drug Outcomes Research, P.O. Box 85222, 3508 AE Utrecht, The Netherlands
2Oncology Biometrics and Epidemiology, Oncology R&D, GlaxoSmithKline, RTP, NC 27709, USA
3The Nationwide Network and Registry for Histo- and Cytopathology in The Netherlands, Foundation PALGA,
Utrecht, The Netherlands
4The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AVL), 1066 CX Amsterdam, The Netherlands
5Department of Medical Informatics, Erasmus University Medical Centre, 3015 GE Rotterdam, The Netherlands
Correspondence should be addressed to Myrthe P. P. van Herk-Sukel, myrthe.van.herk@pharmo.nl
Received 5 March 2012; Accepted 26 March 2012
Academic Editor: Clement Trovik
Copyright © 2012 Myrthe P. P. van Herk-Sukel et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Background. Data is limited on the burden of common comorbidities, such as cardiovascular disease (CVD), respiratory disease
and diabetes, or comorbidities related to cancer and its treatment, such as anemia and depression, in patients with soft tissue
sarcoma (STS). Patients and Methods. From the Dutch Pathology Registry linked to the PHARMO database (including data on
drug use and hospitalizations), 533 patients with STS were selected during 2000–2007 and matched 1:10 to cancer-free controls.
The occurrences of comorbidities were assessed in the 12 months before and after STS diagnosis. Results. STS patients were 2–4
times more likely to have comorbidities at diagnosis compared with cancer-free controls. The incidence of CVD, anemia, and
depression after STS diagnosis diﬀered signiﬁcantly from cancer-free controls and decreased during followup from 40–124 per
1,000 person-years (py) during the ﬁrst six months to 11–38 per 1,000py more than 12 months after diagnosis. The incidence
of respiratory disease and diabetes among STS patients remained stable during followup (5–21 per 1,000py) and did not diﬀer
signiﬁcantly from cancer-free controls. Conclusions. STS patients were more likely to have comorbidities before cancer diagnosis
and to develop CVD, anemia, and depression after diagnosis compared to cancer-free controls.
1.Introduction
Soft tissue sarcomas (STSs) are a rare and heterogeneous
group of tumors arising from mesenchymal tissue [1].
They account for less than 1% of all new malignancies
diagnosed in adults in Europe [2, 3]. STSs show a broad
range of diﬀerentiation and may arise in, for example,
fat (liposarcoma), muscle (smooth muscle: leiomyosarcoma
and striated muscle: rhabdomyosarcoma), and ﬁbrous tissue
(e.g., ﬁbrosarcoma, malignant ﬁbrous hystiocytoma, and
dermatoﬁbrosarcoma) [1]. The most common treatment for
STS is surgical resection with or without radiation therapy
and chemotherapy is administered when metastases are
present [4–6].
Little epidemiologic data on STS is available due to large
variations in tumor biology, histology, location, stage at
presentation, and the relative rarity of these tumors [7]. The
development of STS has been shown to be associated with
environmental factors, immunodeﬁciency, genetic factors,
and viral infection [8, 9]. Important prognostic factors of
STS reported in the literature include tumor size, histology,
primary anatomic site, grade, and the presence of metastatic
disease [8, 10, 11]. The overall survival of patients with STS
has been improving, however this diﬀers per histological
subtype [12, 13]. Many of these patients will have con-
comitant conditions, which has various clinical implications.
Comorbidities are independent determinants of prognosis
(regardless of the chosen therapy) and their presence is also2 Sarcoma
an indicator of the complexity of the clinical needs of each
patient [14].
Previous studies using administrative healthcare data-
bases showed that cardiovascular disease (CVD), respiratory
disease, and diabetes are the most common concomitant
illnessesincancerpatients[14,15].Currently,thereislimited
data available that describes the burden of these comor-
bidities among STS patients. It is important to quantify
these comorbidities as these often necessitate modiﬁcations
of and/or adversely inﬂuence the chosen therapy. Moreover,
less is known about the impact of the most prevalent cancer
symptom: fatigue [16]. Fatigue severely impacts quality of
life and functional capacity. The condition itself is diﬃcult
to measure, but instead one can study treatable contributing
factors like anemia and depression.
This retrospective cohort study describes the prevalence
and incidence of comorbidities including cardiovascular
disease, respiratory disease, diabetes, anemia, and depression
among a population-based cohort of STS patients. These
rates were compared to those observed in a matched
noncancer control population. In addition, risk factors
for developing these morbidities after STS diagnosis were
determined.
2. Methods
2.1. Data Sources. Data from patients with a STS pathology
specimen were obtained from PALGA, the Dutch Nation-
wide Network and Registry of Histo- and Cytopathology.
PALGA contains data of all histological, cytological, and
autopsy examinations in The Netherlands [17]. Currently, it
contains about 42 million abstracts of all pathology reports
with encrypted patient identiﬁcation and diagnostic terms
which are in scope with SNOMED classiﬁcation. PALGA
has achieved complete national coverage since 1990 and
is the basis for the Dutch Cancer Registry. Records from
PALGA were linked to the PHARMO record linkage system
(PHARMO RLS). This linkage has been used in previous
published studies [18, 19]. Data from the PHARMO RLS
consist of multiple observational databases linked on a
patient level, covering 3 million inhabitants of geographic
deﬁned areas in the Netherlands. Databases relevant for
this study include the Dutch National Medical Register [20]
and the community (out-patient) pharmacy database. The
hospital records contain detailed information concerning
admissions for more than 24 hours and admissions for
less than 24 hours for which a bed is required, including
primary and secondary diagnoses, procedures, and dates of
hospital admission and discharge. All diagnoses are coded
according to the International Classiﬁcation of Diseases,
Ninth Revision, Clinical Modiﬁcation (ICD-9-CM). The
drug dispensing histories from community pharmacies con-
tain data on the dispensed drug, prescriber, dispensing
date, amount dispensed, prescribed dose regimens, and thus
the duration of use. All drugs are coded according to the
Anatomical Therapeutic Chemical (ATC) Classiﬁcation.
2.2. Study Population. Patients with a record of a STS
pathology specimen in the period January 1, 2000 to Decem-
ber 31, 2007 were selected from the PALGA database. We
excluded Kaposi’s sarcomas (as these are strongly associated
with herpesvirus [21], and the 2002 WHO classiﬁcation of
STSs does not classify these tumors as a true malignant
sarcoma since there are major uncertainties as to their true
biology [22]) and gastrointestinal stromal tumors (GIST;
as these tumors are largely driven by activating mutations
in the protooncogene KIT, with the protein tyrosine kinase
inhibitor imatinib and sunitinib as speciﬁc treatments for
this tumor [23]). Date of ﬁrst STS pathology specimen
was deﬁned as the cohort entry date. To be able to deﬁne
comorbidities in recent history, patients needed to have at
least 12 months of history in the PHARMO RLS. All patients
were followed from cohort entry until end of data-collection
in the PHARMO RLS (i.e., the patient moves out of the
PHARMO RLS catchment area), death, or end of the study
period (December 31, 2008), whichever occurred ﬁrst.
2.3.Cancer-FreeControls. Theselectionofthecontrolcohort
was stepwise. First, each STS patient was matched 1:20 by
age and gender with a patient from the PHARMO RLS. Each
of these potential controls was assigned the cohort entry date
of the STS patient case match. Potential cases could not be
selected as controls. Second, we eliminated from the pool of
20 possible controls, any control that did not have 12 months
of history before cohort entry date in the PHARMO RLS
and/or who had a hospitalization with a primary diagnosis
for any cancer (ICD-9-CM codes: 140–239) in the period of
ten years before the cohort entry date until December 31,
2008. Finally, out of the remaining controls that fulﬁlled the
above criteria, ten were randomly selected and included in
the control cohort.
2.4. Characteristics. We determined gender, age, and dura-
tion of followup of the patients included in our study cohort.
Topography of the tumor was obtained from PALGA and
classiﬁed as follows: extremities, head and neck, thorax,
abdomenor(retro)peritoneum,andoverlappingsitesorsites
not otherwise speciﬁed. Histologic type of STS was also
obtainedfromPALGAanddeterminedbyusingmorphology
ICD-O-3 codes (International Classiﬁcation of Diseases for
Oncology codes) [24–26]. In addition, data on treatment in
the ﬁrst six months after STS diagnosis was obtained from
the PHARMO RLS. Surgery was assessed based on hospital
procedure codes and the use of chemotherapy was deﬁned
based on hospital discharge diagnoses (ICD-9-CM code:
V581) and/or oral chemotherapies supplied by community
pharmacies (ATC code: L01). Data on radiation therapy was
not available in the data sources of the PHARMO RLS.
2.5. Comorbidities. Comorbidities were deﬁned via hospital
admissions (ICD-9-CM codes) and/or drug dispensings
(ATC codes) captured in the PHARMO RLS. Patients were
considered to have a comorbidity if they either had been
hospitalized for the condition or had been dispensed a
medication used to treat the condition twice in a 365-day
period. For the calculation of incidence rates, the event date
of the ﬁrst of each comorbidity was deﬁned as the date of the
hospitalization or the date of the ﬁrst dispensing, whicheverSarcoma 3
Table 1:Characteristicsofnewlydiagnosedpatientswithsofttissue
sarcoma.
Characteristics
Patients with soft tissue
sarcoma (N = 533)
N (%)
Gender
Male 266 (50)
Female 267 (50)
Age in years
<50 180 (34)
50–<70 211 (40)
≥70 142 (27)
mean ± SD 56 (±20)
Location
Extremities 190 (36)
Head and neck 77 (14)
Thorax 97 (18)
Abdomen or (retro)peritoneum 91 (17)
Overlapping sites and NOS 78 (15)
Histology
Fibrosarcoma (ICD-O-3: 8810-4) 17 (3)
Malignant ﬁbrous hystiocytoma 28 (5)
(ICD-O-3: 8830)
Dermatoﬁbrosarcoma 27 (5)
(ICD-O-3: 8832-3)
Liposarcoma (ICD-O-3: 8850-8) 77 (14)
Leiomyosarcoma (ICD-O-3: 8890-1) 84 (16)
Rhabdomyosarcoma 17 (3)
(ICD-O-3: 8900-1, 8910, 8920)
Synovial sarcoma (ICD-O-3: 9040-3) 9( 2 )
Hemangiosarcoma (ICD-O-3: 912, 22 (4)
913, 915)
Malignant peripheral nerve sheath 16 (3)
tumor (ICD-O-3: 9540, 9560)
Sarcoma, other 63 (12)
Sarcoma, NOS (ICD-O-3: 8800) 173 (32)
Treatment1,2
Surgery 437 (82)
Chemotherapy 55 (10)
SD: standard deviation; NOS: not otherwise speciﬁed; 1no data on
radiotherapy available; 2deﬁned during the ﬁrst six months after soft tissue
sarcoma diagnosis.
came ﬁrst. The following comorbidities were considered:
cardiovascular disease, including heart disease, thrombosis,
and hypertension (ICD-9-CM code: 410, 411, 413, 414,
425–428, 433, 435 or ATC code: B01, C01–C04, C06–
C10), respiratory disease, including asthma, and chronic
obstructive pulmonary disease (ICD-9-CM code: 491–493,
496 or ATC code: R03), diabetes (ICD-9-CM code: 250 or
ATC code: A10), anemia (ICD-9-CM code: 280, 281, 283–
285 or ATC code: B03), or depression (ICD-9-CM code:
296.2, 296.3, 296.82, 298.0, 311, 300.4, 309.0, 309.1, 300.9,
V62.84, 960–979, E950–E959, E980–E989 or ATC code:
N06A).Comorbiditieswereassessedin12months,ofhistory
and during followup (0 to 6 months, 6 to 12 months and 12
months to total followup).
2.6. Analyses. Prevalence proportions in the 12 months
before cohort entry were assessed for each comorbidity and
expressedwithaccompanying95%conﬁdenceintervals(CI).
Conditional logistic regression was used to compare the
prevalenceofthecomorbiditiesbetweentheSTSpatientsand
the cancer-free control group. For incidence calculations,
patients with a prevalent comorbidity (i.e., in the 12
months prior to cohort entry) were removed from the at-
risk population for that speciﬁc event. Incidence rates per
1,000 person-years with accompanying 95% CI based on
Byar’s approximation [27] were calculated for the three
distinct periods of followup time. Cox proportional hazards
regression analysis was used to compare the incidence of
the comorbidities between STS patients and their cancer-free
controls. In addition, Cox proportional hazards regression
models were ﬁt to identify independent risk factors for
developing cardiovascular disease, anemia, and depression
(i.e., the three signiﬁcantly increased comorbidities after
STS diagnosis compared to cancer-free controls) in the
complete followup after STS diagnosis. The patient char-
acteristics mentioned under the subsection Characteristics
were considered as potential risk factors. All risk factors
associated with the outcome in the univariate analyses were
included in the multivariate analyses. Statistical signiﬁcance
was deﬁned at an alpha level of 0.05. Data were analyzed
usingSASprogramsthatareorganizedwithinSASEnterprise
Guide version 4.2 (SAS Institute Inc., Cary, NC, USA). Data
management was conducted under UNIX using SAS version
9.2.
3. Results
A total of 533 patients with a STS resection specimen
between 1 January 2000 and 31 December 2007 were selected
from the PALGA database and linked to the PHARMO RLS
(Table 1). Mean (± standard deviation: SD) age of these
patients was 56 (±20) years and mean (±SD) followup in
the PHARMO RLS was 3.1 (±2.3) years. Most STSs were
situated in the extremities (36%), followed by the thorax
(18%) and the abdomen or (retro)peritoneum (17%). For
a large proportion of tumors, histology was not speciﬁed
(N = 173, 32%). The most common known histological
tumor type was leiomyosarcoma (23% (84/360)), followed
by liposarcoma (21% (77/360)). Treatment in the ﬁrst six
months after STS diagnosis was mainly surgery (82%).
Chemotherapy was administered to 10% of the patients
included in our study cohort.
Table 2 presents the proportion of patients with comor-
bidity in the 12 months before STS diagnosis compared
to cancer-free controls. The most prevalent comorbidity
in STS patients was cardiovascular disease (33%), followed
by respiratory disease (10%), diabetes (7%), anemia (6%),
and depression (6%). Overall, STS patients were twice as
likely as the cancer-free control group to have any of the4 Sarcoma
Table 2:Proportionofpatientswithcomorbidities∗ 12monthsbeforediagnosisofsofttissuesarcoma,comparedtoanoncancerpopulation.
Comorbidity
Patients with soft tissue sarcoma
(N = 533)
Cancer-free control cohort
(N = 5,330) Odds ratio
N (%) N (%) (95% CI)
Cardiovascular disease 178 (33) 1,148 (22) 2.0 (1.7–2.5)
Respiratory disease 54 (10) 262 (5) 2.2 (1.6–3.0)
Diabetes 36 (7) 212 (4) 1.8 (1.2–2.6)
Anemia 31 (6) 92 (2) 3.6 (2.4–5.5)
Depression 34 (6) 177 (3) 2.0 (1.4–2.9)
95% CI: 95% conﬁdence interval; ∗comorbidity deﬁned as either at least 2 dispensings of a relevant drug or a hospitalization for that condition before soft
tissue sarcoma diagnosis.
Table 3: Incidence rates of comorbidities∗ stratiﬁed by followup time since diagnosis of soft tissue sarcoma, compared to a noncancer
population.
Patients with soft tissue sarcoma Cancer-free control cohort Hazard ratio
Events Followup IR per 1,000 Events Followup IR per 1,000 (95% CI)
PY PY (95% CI) PY PY (95% CI)
0 to 6 months after diagnosis
Cardiovascular disease 20 161 124 (75–193) 72 2,004 36 (28–45) 3.7 (2.1–6.3)
Respiratory disease 3 220 14 (5–41) 30 2,444 12 (8–18) 1.1 (0.3–3.7)
Diabetes 2 226 9 (0–31) 9 2,473 4 (2–7) 2.5 (0.5–11.5)
Anemia 19 224 85 (49–134) 31 2,527 12 (8–17) 6.9 (3.8–12.4)
Depression 9 226 40 (18–75) 31 2,486 12 (8–18) 3.2 (1.5–6.9)
6 to 12 months after diagnosis
Cardiovascular disease 8 143 56 (21–112) 52 1,841 28 (21–37) 2.6 (1.2–5.9)
Respiratory disease 4 195 21 (5–51) 16 2,265 7 (4–11) 2.5 (0.8–7.6)
Diabetes 1 202 5 (0–30) 13 2,298 6 (3–10) 0.8 (0.1–6.5)
Anemia 7 194 36 (15–72) 18 2,344 8 (5–12) 5.4 (2.1–13.6)
Depression 1 198 5 (0–30) 23 2,301 10 (7–15) 0.5 (0.1–3.8)
12 months after diagnosis to total followup
Cardiovascular disease 29 762 38 (25–55) 292 10,594 28 (24–31) 1.4 (0.9–2.1)
Respiratory disease 14 1,042 13 (8–22) 78 13,491 6 (5–7) 2.2 (0.9–4.0)
Diabetes 9 1,106 8 (4–15) 69 13,804 5 (4–6) 1.6 (0.8–3.2)
Anemia 12 1,063 11 (6–20) 75 14,036 5 (4–7) 2.3 (1.2–4.4)
Depression 14 1,076 13 (7–21) 91 13,655 7 (5–8) 2.0 (1.1–3.7)
PY: person-years; IR: incidence rate; 95% CI: 95% conﬁdence interval; ∗comorbidity deﬁned as either at least 2 dispensings of a relevant drug or a
hospitalization for that condition after soft tissue sarcoma diagnosis.
comorbidities investigated. The highest odds ratio (OR) was
found for anemia (OR = 3.6, 95% CI: 2.4–5.5).
Incidence rates of the comorbidities are presented for
three distinct periods of followup time (Table 3). The
incidence of cardiovascular disease, anemia and depression
was highest during the ﬁrst six months after STS diagnosis,
124, 85, and 40 per 1,000 person years (py), respectively, and
decreased to 38, 11, and 13 per 1,000 py, respectively, in the
period of 12 months to total followup. The incidence of res-
piratory disease and diabetes among STS patients remained
stable during followup, ranging from 13–21 per 1,000 py
for respiratory disease and 5–9 per 1,000 py for diabetes.
Compared to the cancer-free control cohort, STS patients
were at increased risk for cardiovascular disease (hazard
ratio (HR) = 3.7, 95% CI: 2.1–6.3), anemia (HR = 6.9, 95%
CI: 3.8–12.4), and depression (HR = 3.2, 95% CI: 1.5–
6.9) during the ﬁrst six months after diagnosis. This risk
decreased over time, however, it was still signiﬁcant for
anemia (HR = 2.3, 95% CI: 1.2–4.4) and depression (HR
= 2.0, 95% CI: 1.1–3.7) in the period of 12 months to total
followup. Patients with STS had a similar risk of respiratory
disease and diabetes compared to their cancer-free controls
during the various followup periods, except for the period 12
months after diagnosis to total followup, where patients with
STShadatwotimesincreasedriskofrespiratorydisease(HR
= 2.2, 95% CI: 1.3–4.0).
Multivariate analyses were performed to determine the
risk factors for developing cardiovascular disease, anemia
and depression, that is, the three signiﬁcantly increased
comorbidities after STS diagnosis. Risk factors associatedSarcoma 5
Table 4: Risk factors for developing cardiovascular disease, anemia, and depression after soft tissue sarcoma diagnosis.
Characteristics
Cardiovascular disease Anemia Depression
HR multivariate # 95% CI HR multivariate # 95% CI HR multivariate # 95% CI
Gender
Male 1.9 (1.1–3.5) 1.4 (0.7–2.8) 1.0 (0.4–2.4)
Female 1 reference 1 reference 1 reference
Age in years
<50 1 reference 1 reference 1 reference
50–<70 0.9 (0.4–1.8) 0.7 (0.3–1.8) 1.1 (0.6–2.4)
≥70 1.2 (0.5–2.5) 0.9 (0.3–2.4) 1.5 (0.7–3.5)
Location
Extremities 1 reference
Head and neck 0.8 (0.3–2.0)
Thorax 1.4 (0.6–3.1)
Abdomen or (retro)peritoneum 2.1 (1.1–4.6)
Overlapping sites and NOS 1.9 (0.8–4.7)
Treatment1
Surgery 0.6 (0.2–2.3) 0.7 (0.2–2.6)
Chemotherapy 1.7 (0.7–4.4) 1.9 (1.1–4.1)
NOS:nototherwisespeciﬁed;HR:hazardratio;95%CI:95%conﬁdenceinterval;#themultivariatemodelincludedallfactorsthatwereunivariatelyassociated
with the outcome; 1deﬁned during the ﬁrst six months after soft tissue sarcoma diagnosis.
with the comorbidity in the univariate analyses are presented
in Table 4 and were included in the multivariate analyses.
Independent risk factors for cardiovascular disease after
diagnosis for STS were male gender (HR = 1.9, 95% CI: 1.1–
3.5) and STS located in abdomen or (retro)peritoneum (HR
= 2.1, 95% CI: 1.1–4.6). The only independent risk factor
for developing anemia after STS diagnosis was receiving
chemotherapyduringtheﬁrstsixmonthsafterSTSdiagnosis
(HR = 1.9, 95% CI: 1.1–4.1).
4. Discussion
To our knowledge, this is the ﬁrst population-based study
to report on the prevalence of concomitant diseases at
STS diagnosis and the incidence of comorbidities after STS
diagnosisandtreatment.Weshowedthat33%ofthepatients
with STS suﬀered from cardiovascular disease (including
hypertension) at time of diagnosis, and 10% had evidence
of respiratory disease. Diabetes, anemia, and depression
occurred in 6-7% of the patients at time of diagnosis. In
a previously performed study [14] in The Netherlands on
comorbid conditions among patients diagnosed with one of
the 20 most frequent tumors, similar results were found. In
that study cardiovascular disease (including hypertension)
waspresentin30%ofthepatients,respiratorydiseasein10%
of the patients and diabetes in 7% of the patients [14].
In the current study, STS patients were twice as likely to
have any of the comorbidities prior to diagnosis compared
with the cancer-free control group. This can likely be
attributed to several risk factors that are both related to
the development of the comorbidity and STS such as
immunodeﬁciency, environmental factors, lifestyle factors,
and genetic factors [8, 9].
Cardiovascular diseases, anemia, and depression were
common incident comorbidities, especially in the ﬁrst six
months after STS diagnosis when rates were 124, 85, and
40 per 1,000 py, respectively, and 3–7 times higher than
among cancer-free controls. These incidence rates decreased
during followup, which suggests that cardiovascular diseases,
anemia and depression are comorbidities related to the
cancer itself or its treatment. This was investigated in our
risk factor analysis. We found few signiﬁcant independent
risk factors, which might be explained by the relatively
small patient cohort as STS is a rare tumor. We did
ﬁnd that male gender and STS located in the abdomen
or (retro)peritoneum signiﬁcantly increased the risk of
developing cardiovascular disease after correction for other
risk factors. A possible explanation for this ﬁnding is that
abdominal or (retro)peritoneal STS tumors are mostly larger
and of higher stage at presentation than those located
elsewhere [10]. This may be due to the fact that these tumors
arise in a clinically silent anatomical region where symptoms
develop late in contrast to most head and neck tumors,
which become clinically evident and symptomatic at a small
size. Following this, STS tumors located in the abdomen
might compress or invade other vital organs located in
the abdomen. Second, treatment of abdominal STS tumors
is more invasive and complicated. It is more diﬃcult to
successfully provide a complete operative resection, vital
organs might be damaged due to the surgery or radiation
therapy and following the more advanced stage at diagnosis,
relatively more patients will receive chemotherapy [28].
In addition to risk factors for cardiovascular disease, a
clear association was demonstrated between chemotherapy
in the ﬁrst six months after STS diagnosis and the risk of
anemia during followup. It is well recognized that anemia6 Sarcoma
might arise during or shortly after myelotoxic chemotherapy
[29, 30]. Next to chemotherapy, radiation therapy may fur-
ther negatively impact the severity and incidence of anemia
[31]. Unfortunately we did not have data on radiotherapy
available for all patients included in our study cohort. A
formerDutch study on STS patients in the period 1989–1995
showed that 25% of the STS patients received radiotherapy
with or without surgery and chemotherapy [24]. Analyses
with data from a more recent cohort, the linked Eindhoven
Cancer Registry-PHARMO cohort [32], showed that about
40% of the STS patients in the period 2000–2007 received
radiotherapy.
Next to missing data on radiotherapy, another study
limitationconcernsthewaythecomorbiditieswerecaptured.
In this study we did not use data from general practitioners
or outpatient medical visits. The presence of comorbidities
was based on hospitalizations and/or drug dispensings and
consequently comorbid cases with a mild course were
not included. Furthermore, identifying only the medically
treated depression, limits the ability to directly compare
these results with studies using structured clinical interviews
or screening questionnaires to deﬁne depressive disorders.
Regarding cardiovascular comorbidity, the deﬁnition used is
very broad. However, low numbers of the patients included
in this study did not allow sub classiﬁcation of the results.
Finally, as STSs are a heterogeneous group of tumors
and there is a considerable variation in incidence patterns
of sarcomas by histological type and anatomic site [25],
future studies with larger patient numbers should focus on
determining the comorbidities per histological subtype.
5. Conclusion
This study quantiﬁes the signiﬁcant burden of prevalent
comorbidity in patients diagnosed with STS and presents the
incidence of comorbidity after STS diagnosis and treatment.
Prevalent comorbidity at STS diagnosis implies that more
personalized supportive care is required for these patients.
Incident comorbidity after diagnosis and treatment provides
insight into the pharmacovigilance of STS treatment which
can be used to improve the outcome of these patients.
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